Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Gliosarcoma × rindopepimut × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Brain Neoplasms 1

Interventions

Temozolomide 8 Radiotherapy 5 Procarbazine 4 Radiation 3 Lomustine 3 Carmustine 3 Dihematoporphyrin Ether 2 sargramostim 1 rindopepimut 1 depatuxizumab mafodotin 1 Vincristine 1 Surgical Procedures, Operative 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Conformal 1 Radiosurgery 1 Photons 1 O(6)-benzylguanine 1 Neoadjuvant Therapy 1 Magnetic Resonance Spectroscopy 1 Leflunomide 1 Isotretinoin 1 Immunoglobulin G 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Fentanyl 1 Donepezil 1 Disulfides 1 DNA Methylation 1 Chemotherapy, Adjuvant 1 Bevacizumab 1 ABT-414 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01480479 2018-01-16

ACT IV

Celldex Therapeutics

Phase 3 Completed

Brain Neoplasms, Glioblastoma, Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡